Abnormal Kidney MRI Findings and What Happens Next

Most abnormal findings on a kidney MRI turn out to be benign. Simple cysts account for the majority of unexpected discoveries, and even many solid masses end up being noncancerous growths like angiomyolipomas or oncocytomas. That said, the word “abnormal” on an imaging report understandably triggers anxiety, and what happens next depends heavily on the specific type of abnormality, its size, and its imaging characteristics. The path forward can range from doing nothing at all to years of periodic monitoring to biopsy or surgery.

Cysts Are the Most Common Abnormal Finding

If your kidney MRI report mentions a cyst, you are in very common company. Kidney cysts are so prevalent that roughly half of all adults over 50 have at least one. The vast majority are simple fluid-filled sacs that carry no cancer risk and need no follow-up. The question that matters is whether the cyst has features that make it more complex, like internal walls (septa), calcifications, or areas that take up contrast dye.

Radiologists categorize kidney cysts using the Bosniak classification system, which was updated in 2019 specifically to incorporate MRI findings. The revised system defines previously vague imaging terms more precisely and allows more cysts to be placed in lower-risk categories than the older version did.¹ In practice, applying the 2019 version to MRI improves both sensitivity and specificity for identifying which cystic masses are actually malignant, and most lesions that shift categories get reclassified into the lower-risk IIF group.² The categories run from I (definitely benign, ignore it) through IV (almost certainly malignant, treat it). Category IIF means “probably benign but worth watching,” and categories III and IV generally warrant closer evaluation or intervention.

Solid Masses and What MRI Reveals About Them

A solid mass on kidney MRI is more concerning than a simple cyst, but “solid” does not automatically mean cancer. A meaningful proportion of small solid kidney masses are benign growths. The job of the MRI is to narrow down what the mass is likely to be, based on several imaging features that different tumor types display differently.

Renal cell carcinoma, the most common kidney cancer, has several subtypes that behave differently on MRI. Clear cell RCC, the most frequent subtype, typically appears bright on certain MRI sequences and shows intense early contrast enhancement that washes out quickly. Papillary RCC behaves almost the opposite: it enhances minimally because it has fewer blood vessels, making it appear darker relative to normal kidney tissue on contrast-enhanced images. Chromophobe RCC falls somewhere in between.³ These distinct patterns often allow radiologists to tell subtypes apart without a biopsy.⁴

Angiomyolipomas are the benign growth that most often causes confusion. These masses contain fat, muscle, and blood vessels in varying proportions. When they have abundant fat, they are easy to identify because fat produces a distinctive signal on MRI. The challenge arises with “fat-poor” and “fat-invisible” variants, which contain so little fat that their imaging features overlap with those of kidney cancer.⁵ A systematic review found that MRI shows promising accuracy for detecting these tricky fat-poor angiomyolipomas, performing well enough that it could potentially replace biopsy in selected cases.⁶

One technique that helps sort these masses out is chemical-shift imaging, which detects tiny amounts of fat within a tumor. A drop in signal intensity of more than a certain threshold between two MRI sequences strongly suggests clear cell RCC rather than a fat-poor angiomyolipoma or another cancer subtype. Meanwhile, nearly half of fat-poor angiomyolipomas appear uniformly dark on certain sequences, a pattern rarely seen in clear cell RCC.⁷

How Diffusion-Weighted Imaging Helps Separate Benign From Malignant

Beyond standard contrast-enhanced sequences, kidney MRI often includes diffusion-weighted imaging, which measures how freely water molecules move through tissue. Cancerous tissue tends to be more densely packed with cells, restricting water movement, while benign lesions and cysts allow water to flow more freely. This difference shows up as a measurable number called the apparent diffusion coefficient, or ADC.

Studies consistently show that malignant kidney masses have significantly lower ADC values than benign ones. In one study, the difference was striking enough that the test distinguished benign from malignant lesions with near-perfect accuracy.⁸ Another study found that even among different tumor types, clear cell RCC had distinctly lower ADC values than benign angiomyolipomas and oncocytomas.⁹ Sensitivity for catching malignant masses using this technique runs very high, though specificity is somewhat lower, meaning diffusion-weighted imaging occasionally flags a benign mass as suspicious.¹⁰

In practice, radiologists combine diffusion data with contrast enhancement patterns and standard imaging to form a composite picture. No single sequence provides a definitive answer on its own. The more sequences that point in the same direction, the more confident the interpretation.

When Infection Looks Like Cancer

One scenario that trips up even experienced radiologists is when a kidney infection creates a mass-like abnormality on MRI. Renal abscesses, whether from common bacteria or unusual organisms, can appear as complex cystic masses that look disturbingly similar to cystic kidney cancer.¹¹ The clues that point toward infection rather than cancer include inflammatory changes in the tissue surrounding the kidney, clinical symptoms like fever and flank pain, and a history of urinary tract infections. MRI can be particularly useful in children for diagnosing focal bacterial kidney infections and any abscess complications.¹²

This mimicry matters because it can lead to unnecessary surgery if the clinical context is not considered alongside the imaging. If your MRI shows a suspicious-looking mass but you have also had recent fever, painful urination, or a known infection, your doctor will likely pursue a course of antibiotics and repeat imaging before jumping to a biopsy or surgical plan.

Vascular Abnormalities on Kidney MRI

Not every abnormal kidney MRI finding involves a mass. Renal artery stenosis, a narrowing of the arteries that supply the kidneys, is another important finding that MRI can detect. Contrast-enhanced MR angiography has shown high sensitivity for catching significant narrowing, identifying all significantly stenotic arteries in one study, though it can sometimes overestimate the degree of narrowing.¹³ For patients who cannot receive contrast dye, non-contrast MR angiography is an alternative. It actually achieves higher technical success rates and comparable diagnostic ability for detecting renal artery narrowing without requiring any injected material.¹⁴

Renal artery stenosis matters because it can cause hard-to-control high blood pressure and progressive kidney damage. Finding it on MRI often leads to further evaluation with a vascular specialist, and treatment decisions depend on how severe the narrowing is and whether it is causing measurable effects on kidney function or blood pressure control.

Tracking Polycystic Kidney Disease

For people with autosomal dominant polycystic kidney disease, MRI serves a different purpose: monitoring the total volume of the kidneys over time. In this genetic condition, cysts grow and multiply throughout both kidneys, gradually replacing normal tissue. Total kidney volume measured on MRI has become a key marker for predicting how quickly the disease will progress toward kidney failure.

Different MRI sequences can produce slightly different volume measurements. One study of people with polycystic kidney disease found that volumes measured on one type of sequence were significantly higher than those measured on others, which matters for consistency when tracking changes over years of follow-up.¹⁵ The good news is that the measurement methods themselves are highly reproducible regardless of which radiologist performs them, so the same technique used consistently over time gives reliable trend data.¹⁶

What Happens After a Suspicious Finding

The path after an abnormal kidney MRI depends on where the finding falls on the spectrum from “almost certainly benign” to “likely malignant.” For cystic masses classified as Bosniak IIF, the standard approach is periodic imaging surveillance, typically with repeat CT or MRI. One practical recommendation is imaging every two years after the initial exam, with at least one MRI included during the first four years of follow-up.¹⁷ The vast majority of these lesions, roughly nine out of ten, either stay the same or actually regress over time.¹⁸

Even for Bosniak III lesions, which carry a higher suspicion of malignancy, about half of small ones (under 4 cm) were actually downgraded during active surveillance in the same study. That finding has shifted thinking toward more conservative management for small suspicious cysts. Active surveillance does not appear to increase the risk of cancer spreading or cause worse outcomes for Bosniak IIF and III masses compared to immediate surgery.¹⁹ Bosniak IV lesions, however, carry a high malignancy rate, and surgery remains the primary initial treatment for those.

For small solid masses, the decision is similar but more nuanced. Active surveillance is increasingly accepted for masses under 4 cm, particularly in older adults or those with significant health conditions that make surgery risky. A substantial fraction of these small solid masses are benign, and even among those that are malignant, growth tends to be slow.²⁰ The challenge is that kidney cancer is not one disease. While most small tumors behave indolently, some are aggressive even at small sizes, and there are currently no reliable biomarkers to tell the two apart before treatment.

When Biopsy Enters the Picture

Percutaneous biopsy of kidney masses, performed by inserting a needle through the skin under imaging guidance, has an expanding role. It used to be reserved mainly for cases where cancer had already spread or when infection or lymphoma was suspected. Now it is used more broadly, driven partly by the recognition that a significant proportion of small solid kidney masses are benign and could be spared surgery.²¹

The procedure is safe and accurate. In a large series of over 150 biopsies, sensitivity for detecting malignancy was above 97%, and complications were rare: only about 1% had bleeding that required any attention, and no cases of tumor seeding along the needle track were identified. About 40% of biopsied masses turned out to be benign, and results changed the management plan in more than 60% of cases.²² The most common reasons urologists reach for biopsy include masses in a solitary kidney, bilateral masses, and situations where the patient has a history of a different cancer that might have spread to the kidney.²³

Contrast Dye Safety for People With Kidney Disease

If you already have reduced kidney function, you may have heard warnings about the contrast dye used in MRI. This concern relates to a condition called nephrogenic systemic fibrosis, a serious skin and organ disorder that was linked to certain older gadolinium-based contrast agents in patients with advanced kidney disease. The FDA has contraindicated three specific older-generation agents in at-risk patients.²⁴

The newer agents in routine use today tell a much more reassuring story. A large systematic review that pooled nearly 5,000 patients with stage 4 or 5 chronic kidney disease who received newer-generation agents found zero cases of the condition.²⁵ This does not mean the risk is literally zero, but the upper boundary of risk is very small. For patients who remain concerned or whose kidney function is severely compromised, several MRI techniques work without any contrast at all. Methods like diffusion-weighted imaging and arterial spin labeling can assess blood flow and tissue characteristics without an injection.²⁶

The Psychological Weight of Surveillance

One aspect of abnormal kidney MRI findings that gets far too little attention is the emotional toll of living under surveillance. Being told you have a mass in your kidney and that the plan is to “watch it” can feel deeply unsatisfying, even when the evidence strongly supports that approach. Research has shown that people on active surveillance who have a biopsy-proven malignant tumor experience meaningfully worse psychological distress than patients who have already had their mass treated with surgery or ablation.²⁷

This is worth knowing because it means the distress is real and recognized, not just in your head. If you are on a surveillance protocol and struggling with anxiety about it, raising it with your care team is appropriate. Some centers now build psychological support into their surveillance programs. The decision between watching and treating is increasingly understood as one that should be made collaboratively, weighing not just tumor biology and surgical risk but also how the patient experiences the uncertainty.²⁸

Functional MRI Beyond Mass Detection

Kidney MRI is increasingly used not just to look for lumps but to assess how well the kidneys are working. Several techniques can measure different aspects of kidney function without requiring any contrast dye. Arterial spin labeling estimates blood flow by magnetically tagging the blood itself. Blood oxygen level-dependent (BOLD) imaging maps oxygen levels in kidney tissue, which can reveal early signs of damage before traditional blood tests pick anything up.²⁹ These tools are particularly valuable in transplant recipients, where monitoring the health of the donated kidney over time is critical.³⁰

MRI’s ability to capture perfusion, filtration, water movement, and oxygenation all in a single exam session makes it a uniquely versatile tool for kidney assessment.³¹ In children with congenital kidney and urinary tract anomalies, functional MR urography can evaluate both the anatomy and the degree of any obstruction in a single study, offering an alternative to nuclear medicine scans that involve radiation.³²

Artificial Intelligence and the Future of Kidney MRI Reading

Radiologists are increasingly getting help from machine learning algorithms trained to extract patterns from MRI images that the human eye cannot easily quantify. This field, called radiomics, involves measuring hundreds or thousands of mathematical features within an image and using algorithms to identify which combinations best predict a diagnosis or prognosis.

For kidney tumors, one practical application is predicting tumor grade, which indicates how aggressive a cancer is, without needing a surgical specimen. A machine learning model built on multiple MRI sequences was able to predict nuclear grading for clear cell RCC with high accuracy before surgery.³³ Another study found that combining radiomics with established radiologist assessments produced even better results for distinguishing clear cell RCC from other tumor subtypes than either approach alone.³⁴ More recent work has extended this to “habitat” analysis, where different regions within a tumor are analyzed separately based on their imaging characteristics, further improving the ability to predict tumor grade.³⁵

These tools are not replacing radiologists, but they are giving them an additional layer of information that could eventually reduce the need for biopsies in certain situations. If a machine learning model can predict with high confidence that a mass is low-grade and slow-growing, that might tip the decision toward surveillance over surgery for a borderline case. The technology is still being validated and is not yet standard clinical practice, but the trajectory is clear.